Experimental antibody combo tackles Hard-to-Treat cancers
Disease control
Completed
This early-phase trial tested an experimental drug called ADG116, which helps the immune system attack cancer cells. The study included 72 adults with advanced solid tumors that had stopped responding to standard treatments. Some participants received ADG116 alone, while others g…
Phase: PHASE1 • Sponsor: Adagene Inc • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC